1. Scrip
  2. >>Therapy Areas
  3. >>Antiparasitic

Serum-Biocon Deal Sees COVID Reality Tweak Even As Oxford’s Malaria Vaccine Holds Promise

HPV Vaccine India Tender Keenly Awaited

 
• By Vibha Ravi

Gains from its COVID-19 vaccine made Serum Institute’s founder the world’s richest healthcare billionaire. But the demand for boosters hasn’t materialized as expected, leading to a deal with Biocon being tweaked. Meanwhile, gains from India’s first indigenously-developed HPV vaccine and Oxford-partnered malaria vaccine seem imminent.

Partnership concept
The Serum-Biocon Deal Has Factored In Changed Realities • Source: Shutterstock

In 2021, Serum Institute of India Pvt. Ltd. subsidiary Serum Institute of Life Sciences (SILS) entered a deal with Biocon, Ltd. arm Biocon Biologics to acquire a 15% stake in exchange for a $150m cash infusion and access to a vaccine pipeline that would have included COVID-19 and other vaccines.

The deal made sense as it gave Serum Institute an entry into the world of non-vaccine biologicals - developing a biosimilar is estimated to cost $80-100m, excluding switching studies required...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Antiparasitic

Novartis Measures Malaria Success On Impact Rather Than Money

 
• By Kevin Grogan

The Swiss major’s global health chief Lutz Hegemann tells Scrip on a trip to Rwanda that being a profitable enterprise while helping to improve access to new and older therapies for those who need it most is the real measure of a successful business.

Tarsus Demonstrates Lotilaner’s Potential In Preventing Lyme Disease

 
• By Joseph Haas

Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.

Serum-Biocon Deal Sees COVID Reality Tweak Even As Oxford’s Malaria Vaccine Holds Promise

 
• By Vibha Ravi

Gains from its COVID-19 vaccine made Serum Institute’s founder the world’s richest healthcare billionaire. But the demand for boosters hasn’t materialized as expected, leading to a deal with Biocon being tweaked. Meanwhile, gains from India’s first indigenously-developed HPV vaccine and Oxford-partnered malaria vaccine seem imminent.

Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’

 
• By Joseph Haas

Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.

More from Scrip

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Executives On The Move: Capricor Therapeutics Acquires Chief Medical Officer From Pfizer, Galapagos And Cellarity Get A New CEO, And More

Recent moves in the industry include new C-suite hires at Janux Therapeutics, BlueSphere Bio and Hansa Biopharma, plus Syndax Pharmaceuticals gets new chief medical officer from Bristol Myers Squibb.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.